First Time Loading...

Madrigal Pharmaceuticals Inc
NASDAQ:MDGL

Watchlist Manager
Madrigal Pharmaceuticals Inc Logo
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Watchlist
Price: 216.05 USD 2.59% Market Closed
Updated: May 3, 2024
Section:
 

Wall Street
Price Targets

MDGL Price Targets Summary
Madrigal Pharmaceuticals Inc

Wall Street analysts forecast MDGL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MDGL is 384.61 USD with a low forecast of 151.5 USD and a high forecast of 593.25 USD.

MDGL Lowest Forecast
Wall Street Target
151.5 USD
30% Downside
MDGL Average Forecast
Wall Street Target
384.61 USD
78% Upside
MDGL Highest Forecast
Wall Street Target
593.25 USD
175% Upside
Lowest
Price Target
151.5 USD
30% Downside
Average
Price Target
384.61 USD
78% Upside
Highest
Price Target
593.25 USD
175% Upside

MDGL Last Price Targets
Madrigal Pharmaceuticals Inc

The latest public price target was made on Mar 19, 2024 by Liisa Bayko from Evercore ISI , who expects MDGL stock to rise by 87% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Liisa Bayko
Evercore ISI
405 USD
Upside 87%
1 month ago
Mar 19, 2024
Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at Evercore ISI, 'well positioned to execute on the launch of Rezdiffra'
StreetInsider
Akash Tewari
Jefferies
400 USD
Upside 85%
1 month ago
Mar 15, 2024
Madrigal Pharmaceuticals (MDGL) PT Raised to $400 at Jefferies, 'label hit our bull case'
StreetInsider
Eliana Merle
UBS
410 USD
Upside 90%
1 month ago
Mar 15, 2024
Madrigal Pharmaceuticals (MDGL) PT Raised to $410 at UBS
StreetInsider
Mayank Mamtani
B.Riley Financial
270 USD
Upside 25%
1 month ago
Mar 15, 2024
B.Riley Upgrades Madrigal Pharmaceuticals (MDGL) to Neutral
StreetInsider
Jonathan Wolleben
JMP Securities
397 USD
Upside 84%
1 month ago
Mar 15, 2024
Madrigal Pharmaceuticals (MDGL) PT Raised to $397 at JMP Securities, ' We had strong conviction'
StreetInsider
Ed Acre
H.C. Wainwright
425 USD
Upside 97%
1 month ago
Mar 15, 2024
Madrigal Pharmaceuticals (MDGL) PT Raised to $425 at H.C. Wainwright, 'Rezdiffra Achieves Landmark Approval'
StreetInsider
Show More Price Targets
Show Less Price Targets
Liisa Bayko
Evercore ISI
Price Target 405 USD
Upside/Downside 87%
View Source
Akash Tewari
Jefferies
Price Target 400 USD
Upside/Downside 85%
View Source
Eliana Merle
UBS
Price Target 410 USD
Upside/Downside 90%
View Source
Mayank Mamtani
B.Riley Financial
Price Target 270 USD
Upside/Downside 25%
View Source
Jonathan Wolleben
JMP Securities
Price Target 397 USD
Upside/Downside 84%
View Source
Ed Acre
H.C. Wainwright
Price Target 425 USD
Upside/Downside 97%
View Source
Show More Price Targets
Show Less Price Targets
Madrigal Pharmaceuticals Inc Competitors:
Price Targets
PBYI
Puma Biotechnology Inc
11% Downside
VCYT
Veracyte Inc
50% Upside
ARGX
argenx SE
27% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
35% Upside
PBYI
Puma Biotechnology Inc
11% Downside
VCYT
Veracyte Inc
50% Upside
ARGX
argenx SE
27% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
35% Upside
IMMU
Mendus AB (publ)
174% Upside
LEGN
Legend Biotech Corp
91% Upside
J
7774
Japan Tissue Engineering Co Ltd
92% Upside
XBIT
XBiotech Inc
124% Upside

Revenue
Forecast

Revenue Estimate
Madrigal Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Madrigal Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Madrigal Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-29%
Average Miss
What are analyst estimates?

See Also

Summary
MDGL intrinsic value, competitors valuation, and company profile.
DCF Valuation
MDGL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MDGL stock valuation using valuation multiples.
Wall Street Estimates
MDGL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MDGL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MDGL's stock price target?
Price Target
384.61 USD

According to Wall Street analysts, the average 1-year price target for MDGL is 384.61 USD with a low forecast of 151.5 USD and a high forecast of 593.25 USD.

ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.